Merck & Co.
AWARDS
NEWS
Each year, Peter Drucker’s Drucker Institute generates its Management Top 250, evaluating companies based on what it calls five dimensions of corporate performance. Those five dimensions are Customer Satisfaction, Employee Engagement and Development, Innovation, Social Responsibility and Financial Strength.
The U.S. Food and Drug Administration has had a busy August. In addition to the number of draft guidance documents the agency issued during the month, the FDA has also been busy approving a number of new treatments for a variety of diseases.
Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
Only a month after raising $85.4 million in a Series E financing, Sutro Biopharma filed for an initial public offering (IPO). The company plans to raise $75 million with the IPO.
Bristol-Myers Squibb has appointed Christopher Boerner to replace Murdo Gordon, who left the company on August 3. Boerner will take on the positions of executive vice president and chief commercial officer, effective immediately.
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
JOBS
IN THE PRESS